Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Neogenomics Inc
(NQ:
NEO
)
16.24
-0.24 (-1.46%)
Streaming Delayed Price
Updated: 12:10 PM EDT, Aug 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Neogenomics Inc
< Previous
1
2
3
4
5
6
Next >
Lost Money in NeoGenomics, Inc.?
May 24, 2022
From
Gibbs Law Group
Via
Business Wire
Lost Money in NeoGenomics, Inc.?
May 16, 2022
From
Gibbs Law Group
Via
Business Wire
NeoGenomics Appoints Lynn Tetrault Interim CEO
May 16, 2022
FT. MYERS, FL / ACCESSWIRE / May 16, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetic testing services and global oncology contract research services,...
From
NeoGenomics, Inc.
Via
AccessWire
NeoGenomics, Inc. (NASDAQ: NEO) Investor Notice: Investigation over Possible Violations of Securities Laws
May 11, 2022
San Diego, CA -- (SBWIRE) -- 05/11/2022 -- NeoGenomics, Inc is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Present New Data Further Validating the Application of its RaDaR(R) MRD and InVisionFirst(R)-Lung Tests at the 2022 ASCO Annual Meeting
May 10, 2022
FT. MYERS, FL / ACCESSWIRE / May 10, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced...
From
NeoGenomics, Inc.
Via
AccessWire
NeoGenomics Announces Leadership Transition Appointing Vishal Sikri as President and Chief Commercial Officer of Inivata Liquid Biopsy Subsidiary
May 09, 2022
FT. MYERS, FL / ACCESSWIRE / May 9, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced the...
From
NeoGenomics, Inc.
Via
AccessWire
NeoGenomics To Participate in the BofA Securities 2022 Healthcare Conference
May 05, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
From
NeoGenomics, Inc.
Via
AccessWire
NeoGenomics Reports Revenue of $117 Million in the First Quarter
April 27, 2022
First-Quarter 2022 Results - Consolidated revenue increased 1% to $117 million; excluding 2021 COVID-19 PCR testing revenue, consolidated revenue increased 3% - Clinical Services revenue increased 2%...
From
NeoGenomics, Inc.
Via
AccessWire
Exposures
COVID-19
NeoGenomics Inc. Announces Partnership with Lilly for Lung Cancer Sponsored Testing Program Utilizing the NeoTYPE(R) DNA and RNA Assay
April 25, 2022
FT. MYERS, FL / ACCESSWIRE / April 25, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced...
From
NeoGenomics, Inc.
Via
AccessWire
NeoGenomics Announces That Inivata Liquid Biopsy Subsidiary and Collaborators Have Published Clinical Validation Data for RaDaR(TM) Assay MRD Assay at AACR 2022
April 11, 2022
Data demonstrates potential of RaDaR to predict clinical response in stage III urothelial cancer FT. MYERS, FL / ACCESSWIRE / April 11, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of...
From
NeoGenomics, Inc.
Via
AccessWire
NeoGenomics, Inc. Expands Its Global Strategic Partnership Initiatives with Biognosys AG on Multiple Next Generation Proteomics Solutions Supporting Biopharma R&D
April 11, 2022
NeoGenomics continues to add to its state-of-the-art multiomics solutions in world-class biopharma clinical trial and research services for global pharma companies FORT MYERS, FL / ACCESSWIRE / April...
From
NeoGenomics, Inc.
Via
AccessWire
NeoGenomics Schedules its First Quarter 2022 Earnings Release for April 27, 2022
April 08, 2022
FT. MYERS, FL / ACCESSWIRE / April 8, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to...
From
NeoGenomics, Inc.
Via
AccessWire
NEOGENOMICS ALERT: Bragar Eagel & Squire, P.C. is Investigating NeoGenomics, Inc. on Behalf of NeoGenomics Stockholders and Encourages Investors to Contact the Firm
April 01, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Lost Money in NeoGenomics, Inc.?
March 31, 2022
From
Gibbs Law Group
Via
Business Wire
NEOGENOMICS ALERT: Bragar Eagel & Squire, P.C. is Investigating NeoGenomics, Inc. on Behalf of NeoGenomics Stockholders and Encourages Investors to Contact the Firm
March 31, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages NeoGenomics, Inc. Investors with Losses to Inquire About Securities Class Action Investigation – NEO
March 31, 2022
From
The Rosen Law Firm, P.A.
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors
March 30, 2022
From
Glancy Prongay & Murray LLP
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors
March 30, 2022
From
Law Offices of Howard G. Smith
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors
March 29, 2022
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Kirby McInerney LLP Announces an Investigation of Shareholder Claims on Behalf of NeoGenomics, Inc. (NEO) Investors
March 29, 2022
From
Kirby McInerney LLP
Via
Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in NeoGenomics, Inc. with Losses of $100,000 to Contact the Firm
March 29, 2022
From
The Schall Law Firm
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in NeoGenomics, Inc. with Losses of $100,000 to Contact the Firm
March 28, 2022
From
The Schall Law Firm
Via
Business Wire
SHAREHOLDER ALERT - Labaton Sucharow Investigating NeoGenomics Inc. - NEO
March 28, 2022
From
Labaton Sucharow LLP
Via
Business Wire
NeoGenomics Announces CEO Departure and Initiates CEO Search
March 28, 2022
Board Appoints Executive Chair and Interim Office of the CEO Anticipates First Quarter Results Below Guidance and Withdraws 2022 Guidance FT. MYERS, FL / ACCESSWIRE / March 28, 2022 / NeoGenomics, Inc....
From
NeoGenomics, Inc.
Via
AccessWire
NeoGenomics Announces That Inivata Liquid Biopsy Subsidiary and Collaborators Have Published Clinical Validation Data for RaDaR(TM) Assay in Non-Small Cell Lung Cancer
March 17, 2022
Study further highlights potential of RaDaR to stratify patients and improve treatment outcomes FT. MYERS, FL / ACCESSWIRE / March 17, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of...
From
NeoGenomics, Inc.
Via
AccessWire
NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences
March 02, 2022
FT MYERS, FL / ACCESSWIRE / March 2, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced...
From
NeoGenomics, Inc.
Via
AccessWire
NeoGenomics Reports Full Year Revenue of $484 Million and $126 Million for the Fourth Quarter of 2021
February 23, 2022
Recent Highlights: - Full year 2021 consolidated revenue increased 9% year-over-year; excluding COVID-19 PCR testing revenue, consolidated revenue increased 16% - Fourth quarter consolidated revenue...
From
NeoGenomics, Inc.
Via
AccessWire
Exposures
COVID-19
NeoGenomics appoints Dr. Shashi Kulkarni, a World-Renowned Oncology Genomics Expert, and Innovator as Chief Scientific Officer
February 14, 2022
FT. MYERS, FL / ACCESSWIRE / February 14, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, has...
From
NeoGenomics, Inc.
Via
AccessWire
NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Publish Positive Results from Prospective Clinical Study of RaDaR(TM) in Head and Neck Squamous Cell Carcinoma
February 11, 2022
RaDaR demonstrated 100% specificity in patients with no recurrence and 100% sensitivity in patients with clinical recurrence FT MYERS, FL / ACCESSWIRE / February 11, 2022 / NeoGenomics, Inc....
From
NeoGenomics, Inc.
Via
AccessWire
NeoGenomics to Participate Virtually in Multiple Upcoming Institutional Investor Conferences
February 08, 2022
FT. MYERS, FL / ACCESSWIRE / February 8, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today...
From
NeoGenomics, Inc.
Via
AccessWire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.